ArticleScientific reports2025
Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Expanding the conditioning armamentarium in adult acute lymphoblastic leukaemia: is treosulfan ready to challenge total body irradiation?Bone marrow transplantation · 2026Article
- Early Secondary Graft Failure After Complete Donor Chimerism with Autologous Recovery Following Haploidentical HSCT for Relapsed B-ALL.Blood cell therapy · 2026Article
- MRD-guided de-escalation of TBI conditioning in ALL.Bone marrow transplantation · 2026Article
- CAR-T versus allogeneic transplantation as consolidation for B-cell acute lymphoblastic leukemia in remission: a propensity-score matched study.Frontiers in immunology · 2026Article
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.Cancers · 2025Review
- Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best conditioning for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia is debated. We analyzed 178 adults undergoing HSCT with total body irradiation (TBI) or chemotherapy conditioning regimens for B-cell leukemia in complete remission 1 (CR1). Both TBI and chemotherapy regimens showed comparable overall survival (OS) and leukemia-free survival (LFS). However, TBI had a trend of reduced relapse (HR 0.56, P = 0.064) but higher non-relapse mortality (NRM, HR 3.23, P = 0.072) due to increased grade 3 to 4 graft-versus-host disease (22.8% vs. 8.8%, P = 0.023). The key factor affecting survival was minimal residual disease (MRD) after three chemotherapy cycles (OS P = 0.004, LFS P = 0.006). In MRD-negative patients, both regimens gave similar LFS and cumulative incidence of relapse (CIR) irrespective of whether the transplantation was allogeneic (allo-HSCT) or autologous (auto-HSCT), but the allo-HSCT group had a lower OS due to higher NRM (5.3% vs. 20.6%, P = 0.020). For MRD-positive patients, TBI was superior in LFS (71.9% vs. 43.9%, P = 0.017) and relapse rate (18.5% vs. 48.7%, P = 0.006). Our research indicates the choice between TBI and non-TBI should be based on MRD after three chemotherapy cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.